Review Article
Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
Table 3
Completed clinical trials of bevacizumab combined with chemotherapy in ovarian cancer.
| Trial number | Phase | Chemotherapy | Stage of the disease | Number of patients | Outcomes |
| NCT00127920 (AV53206s) [39] | II | Carboplatin + paclitaxel | Newly diagnosed stage III/IV | 20 | CR: 30% PR: 50% | NCT00072566 (NCI-5789) [40] | II | Metronomic cyclophosphamide | Platinum-sensitive recurrent | 70 | CR: 0 PR: 24% MPFS: 7.2 (m) MOS: 16.9 (m) | NCT00129727 (OVCA) [41] | II | Carboplatin + paclitaxel + bevacizumab + maintenance bevacizumab | Newly diagnosed stage ≥ IC | 62 | CT: CR: 56% PR: 22% Ca-125: CR: 89% PR: 7% | NCT00343044 (3040200, AVF3648s)* | II | Topotecan | Platinum-resistant recurrent EOC, PPC, FTC | N/A | N/A |
|
|
CR: complete response, PR: partial response, MPFS: median progression-free survival, m: months, MOS: median overall survival (months), EOC: epithelial ovarian cancer, PPC: primary peritoneal cancer, FTC: fallopian tube cancer.
*Accessed from http://www.clinicaltrials.gov/ on April 18, 2011.
|